Stop TB Partnership

New funding for two vaccine candidates

14 January 2013 - Lelystad, the Netherlands - The vaccine candidates MTBVAC, developed by the University of Zaragoza and produced by BIOFABRI, and HBHA, developed by Institute Pasteur Lille and produced in collaboration with AERAS, have been awarded financial support for further development. BIOFABRI will receive US$ 430,000 to support a Phase I clinical trial to be carried out by Centre Hospitalier Universitaire Vaudois, Lausanne. Institut Pasteur Lille will receive US$ 350,000 to fund production of HBHA and studies to select an adjuvant.

The funding follows a Tuberculosis Vaccine Initiative (TBVI) call for proposals last June for early clinical development of new, promising TB vaccine candidates.